Английская Википедия:ACT-539313
Шаблон:Short description Шаблон:Drugbox
ACT-539313 is an orexin antagonist medication which is under development for the treatment of binge eating disorder and was previously under development for the treatment of anxiety disorders.[1][2][3][4][5][6] It is an orally active small-molecule compound with an elimination half-life of 3.3 to 6.5Шаблон:Nbsphours and acts as a selective orexin OX1 receptor antagonist (1-SORA).[1][5][6] As of May 2022, the drug is in phase 2 clinical trials for binge eating disorder.[1] Following negative efficacy results of a phase 2 trial of ACT-539313 for binge eating disorder, Idorsia (the developer of ACT-539313) signaled in May 2022 that it would not pursue further development of the drug for this indication.[7]
References
Шаблон:Orexin receptor modulators
Шаблон:Nervous-system-drug-stub